Arts and Culture
More from Google
Get the Android app
Get the iOS app
WCG Institute Podcast: Pioneers of Clinical Research
Insights from leaders in clinical research and trial optimization, hosted by the WCG Institute.
Jun 12, 2020
Dorelia Rivera talks about health disparities, a career in advocacy and saving her daughter’s life
Our guest this episode, patient advocate Dorelia Rivera, improves access to healthcare services and clinical trials for the underrepresented, including her own Hispanic community. Her advocacy ranges from community volunteer work, to jobs for a state health and human services department, a payor, and a rare disease drug company. She advocates on Capitol Hill and served on the National Institutes of Health Advisory Council on Diversity She’s also a mother of a child with a rare disease. Rivera’s daughter has an ultra-rare condition, NOMID--neonatal onset multisystem inflammatory disease. When she was first diagnosed, the doctor said she wouldn’t live to be 10 years old. Today, she is thriving teenager, thanks to an NIH clinical trial and her mother’s persistence. Rivera talks about her daughter and her advocacy for underserved communities. Like those with rare diseases, racial and ethnic minorities are too often overlooked. “Health disparities are real,” she says. The COVID-19 pandemic and the current protests are driving that home, she adds. “It’s painfully, painfully, painfully evident.” Changes need to be made concurrently across several areas, including insurance coverage, access to care, access to clinical trials, and a greater focus on the social determinants of health. “Healthcare should be a right, not a privilege.” In terms of clinical trials, sponsors need to understand the barriers many patients--especially those in minority communities--face. Someone who needs to leave work to participate in a trial may not have a job when they return. Too often, trial sponsors aren’t flexible in addressing the obstacles potential participants face. If sponsors want to improve diversity, they need to level the playing field. “They have to meet the families where they are.”
Jun 12, 2020
It’s all about the trust: Authentic community engagement key to diverse trial enrollment
“Our research population should match our community population.” That’s one of the takeaways from Christopher Gantz’s interview with WCG President of Patient Advocacy Steve Smith. He describes several programs that help connect researchers with minority communities to increase engagement and access enrollment in clinical trials. Gantz is senior director of the Regional Liaison Office at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson Hospital in Philadelphia. Since 2005, he has worked on multiple clinical trials projects with recruitment goals ranging from 500 to 10,000 participants. He describes establishing an “honest broker network” and engagement of resources within the hospital and within the community to ease communication, build trust and facilitate trial enrollment. He also discusses some of SKCC’s language and cultural resources as well as its outreach into area schools. Listen to learn how SKCC’s success offers a model for other organizations to transform clinical trials. “We have so many resources and so many opportunities to engage with people. I think if we're smart about it and really thoughtful in how we do it and create these longstanding relationships, it really will create a change.”
Jun 8, 2020
Communicating the Value of Clinical Trials to Underserved Minority Communities
In this episode, we learn about CISCRP’s AWARE for All campaign, which builds awareness of, creates access to and encourages participation in clinical trials. Ellyn Getz, Associate Director of Development and Community Engagement at CISCRP, The Center for Information and Study on Clinical Research Participation, discusses AWARE for All. CISCRP's flagship grassroots campaign works with diverse communities around the world to build a greater awareness and understanding of the clinical research process and the role that participation plays in advancing public health. This program is a response to health disparities in these communities—disparities rooted in the long-standing lack of access to healthcare, and gaps in understanding between these communities and the healthcare system. Each AWARE for All event brings together a diverse array of stakeholders, including community groups, local researchers, patient advocates and community members. “Hearing from local study volunteers and local researchers is one of the most uplifting parts of this program, especially if [attendees] can hear about breakthroughs or really exciting developments and advancements in research that are taking place in their own community,” she reports. Weeks of planning with community leaders culminates in a free community health event. Although usually done onsite and in person, the next event, on July 16, will be virtual. This will allow people to watch it live or access the information later. In addition to presentations, it will include a virtual exhibit fair with community health assessments. Details are available here: awareforall.org.
Jun 3, 2020
People, Process and Technology: The Right Combination for Successful Expert Committees
Independent expert committees provide essential validation of clinical data. Without their insights, sponsors risk missed signals, conflicts of interest and costly delays. But establishing a successful expert committee can be tricky. It requires the right combination of people, process and technology. In this three-part podcast, Lakshmi Sundar, head of business transformation at WCG ACI Clinical, explores each of these with a WCG ACI expert. In the first part of the series, Bill Stedman, manager of member services, shares his perspective on the “people” aspect. He discusses how success rests on having the right combination of expertise. Then, Dr. Bindi Shah, chief medical officer, explains how proper processes are critical to setting and running up expert committees. In the final part of the series, Mandy Moran, manager, innovation and technology, discusses how, when deployed correctly, technology supports the people and the process, allowing committee members do what they do best and do it efficiently.
May 15, 2020
Bringing Clinical Trials Closer to Home: Smaller, Local Sites Build Trust & Provide Access to Local Communities
In this episode, Dolly Niles, executive director of QUEST Research Institute, talks about the role of small research sites and the value of community outreach. QUEST, a multi-specialty independent research site in metro Detroit, has conducted more than 350 phase 1-4 trials since it was established in 1996. Niles talks about the role of agile smaller sites during the height of the COVID-19 pandemic. Many health systems and academic medical centers reassigned research staff to patient floors. Smaller sites like QUEST Research Institute have been able to step up, contract quickly and stand up new studies while completing current ones. She also touches on the importance of connecting with the local community--including minority communities. The fact that COVID-19 is hitting minority populations particularly hard “highlights something we already know--that minority communities are underrepresented in clinical research,” she says. “Sites need to spend time figuring out how to crack that nut.” The issue goes far beyond recruitment, she says. It requires educating patients and physicians about clinical trials. It involves establishing a trust relationship so when it’s time to recruit, potential participants have that relationship and want to know more. “We need to figure out how to make time for that.”
May 6, 2020
Raise Your Voices: Social Network Provides Safe Place for Patients to Share Stories and Influence Research
In this episode, Brian Loew, founder and CEO of online patient portal Inspire, talks about the value to patients and caregivers of providing a safe and trustworthy online social network--a “peaceable kingdom,” as he calls it. Millions of patients representing 3,500 diseases--including many rare ones --come to Inspire.com for online community discussions focused on their own particular disease. The platform provides a place for meaningful conversations among patients and caregivers. It also allows them to share their insights in ways that advance clinical research. Patients want to support research, sometimes even initiating it themselves. And, more than ever, Loew says, researchers are interested in patient-reported information. If patients agree, they can also be connected to relevant clinical trials. Loew emphasizes that across all the conditions and forums, patients always have control over what data they share and where they share it--and in his experience, the more control they have, the more willing they are to share it. The recently added coronavirus section (www.inspire.com/coronavirus) also features video testimonials from patients with a variety of conditions describing why COVID-19 is disrupting their medical routines and threatening their health. Loew is a frequent speaker and writer on the topics of health-focused social networks and digital health. He sits on the boards of the Robert Packard Center for ALS Research at Johns Hopkins, and New Jersey Goals of Care. He was a “Red Jacket” recipient from PharmaVOICE magazine for his contributions to the industry.
Apr 28, 2020
Advocating for Transformation and Change in Rare Disease Drug Development: An Interview with Frank Sasinowski
Drug policy has transformed to bring transformative improvement to the way rare diseases are developed resulting in more FDA approved treatments. This transformation came about because of collaboration across stakeholders: patient advocates, the FDA, Congress, drug developers, researchers, and legal specialists. Profound change came in the mid 1980’s when AIDS activists, Rare Disease Activists, and others found ways to use policy to accelerate development of FDA approved treatments. Legal specialists Frank Sasinowski of Hymen Phelps and McNamara has always been a champion of the patient voice in legislative change, drug development policy, and FDA approvals. In this WCG Patient Radio episode with WCG’s President of Patient Advocacy, Steve Smith, Mr. Sasinowski speaks of the transition from a time in the late 90s when patients were not even considered in drug policy. He speaks of formalization of the patient voice into legislation, the Rare Disease Congressional Caucus, Patient-Centric Drug Development program at the FDA, and numerous other transformative mechanisms. Change is evident as we now see many patient-focused roles within drug development companies, working with more sophisticated patient advocacy groups, and regulators. During this 20 minute podcast, Mr. Sasinowski also discusses the balance between the need for speed of drug development, with safety, and the concept of “certainty.” How can we include, in the drug approval process, the concept of “risk vs. benefit” as seen by patients that are in need of a therapy very soon who are willing to take more risk.
Apr 28, 2020
Raise Your Voices: Social Network Provides Safe Place for Patients to Share Stories and Influence Research
In this episode, Brian Loew, founder and CEO of online patient portal Inspire, talks about the value to patients and caregivers of providing a safe and trustworthy online social network: a “peaceable kingdom,” as he calls it. Millions of patients representing 3,500 diseases—including many rare ones—come to Inspire.com for online community discussions focused on their own particular disease. The platform provides a place for meaningful conversations among patients and caregivers. It also allows them to share their insights in ways that advance clinical research. Patients want to support research, sometimes even initiating it themselves. And, more than ever, Loew says, researchers are interested in patient-reported information. If patients agree, they can also be connected to relevant clinical trials. Loew emphasizes that across all the conditions and forums, patients always have control over what data they share and where they share it—and in his experience, the more control they have, the more willing they are to share it. The recently added coronavirus section (Inspire.com/coronavirus) also features video testimonials from patients with a variety of conditions describing why COVID-19 is disrupting their medical routines and threatening their health. Loew is a frequent speaker and writer on the topics of health-focused social networks and digital health. He sits on the boards of the Robert Packard Center for ALS Research at Johns Hopkins, and New Jersey Goals of Care. He was a “Red Jacket” recipient from PharmaVOICE magazine for his contributions to the industry.
Apr 21, 2020
Getting the Word Out About Prostate Cancer with Entrepreneur, Engineer, Advocate and Survivor Thomas Farrington
In this podcast, Thomas Farrington, founder of the Prostate Health Network, speaks with WCG President of Patient Advocacy Steve Smith. Mr. Farrington discusses his experience with the healthcare system, coupled with his own research on prostate cancer, which led him to become a vocal advocate for prostate cancer patients and survivors. His advocacy spans a wide range of approaches from educational seminars, a frequently-visited website, a theater production called Daddy’s Boy that is now on tour, and visits to legislators on Capitol Hill to help shape public policy for the benefit of people with this unmet medical need. Mr. Farrington also serves as a trustee of the Dana Farber Cancer Institute and as an advisor to a number of other healthcare organizations and programs, and he is on the National Comprehensive Cancer Network’s prostate cancer treatment guidelines panel and their prostate cancer early-detection guidelines panel.
Apr 17, 2020
We Should Not Be Surprised: COVID-19 Disparities Lay Bare What’s Been There All Along
In this episode, former Assistant FDA Commissioner Jonca Bull, MD, discusses racial disparities in healthcare, how COVID-19 has made them impossible to ignore, and how this highlights the need for diversity in clinical trials. Low-income minority communities are being hit disproportionately hard by COVID-19. Dr. Bull isn’t surprised: The current crisis has simply magnified existing disparities. A multitude of factors are at play, including lack of access to healthcare and healthful food. As a result of these and other issues, certain underlying health conditions are more prevalent in low-income minority communities. Clinical trials must include these populations so we can truly understand COVID-19 and how to treat it in real-world conditions. In fact, the FDA has long had guidance on how to make trials more diverse: * Collection of Race and Ethnicity Data in Clinical Trials—Guidance for Industry and Food and Drug Administration Staff * Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs: Guidance for Industry She emphasizes that African Americans are willing--sometimes more willing than others--to participate in clinical trials. But they must be invited, and trials must be designed with consideration of the obstacles they face because of where they live and how they work. Dr. Bull serves as a consultant focused on drug development and regulatory considerations; she helps guide the strategic development and implementation of clinical trial protocols. She has served in various roles, including as assistant commissioner at FDA with a focus on diverse populations and clinical trials.
Apr 15, 2020
COVID-19 Doesn’t Play Fair: What We Need to Understand About Racial Disparities
This episode takes on a topic from recent headlines--namely, the racial disparity in COVID-19 cases and deaths. Edith P. Mitchell, MD, MACP, FCPP, shares her insights on the causes of these health disparities and how they relate to the coronavirus. Contributing factors include less access to testing, lack of insurance and paid time off, underlying health conditions, and the spread of misinformation about the virus. She also touches on how racial disparities affect clinical research. “When I came to Philadelphia, we had only 7.8% participation by African Americans in clinical trials. Yet 45% of Philadelphia is African American. We have been able to raise the participation in clinical trials to a high of 24.9%, and maintain a range around 20%,” she tells WCG President of Patient Advocacy Steve Smith. “Never assume African Americans don’t want to participate in clinical trials. They must be invited, and there must be cultural competence among healthcare providers.” Dr. Mitchel…
Apr 1, 2020
The Patient Perspective: Facing COVID-19 with Research, Action, and Hope
In this COVID-19 focused episode, Dr. David Fajgenbaum chats with President of WCG Patient Advocacy, Steve Smith, to talk about his journey as a medical researcher and patient of a rare disease and about the pandemic facing our daily lives. Known for his best-selling book, Chasing My Cure: Turning Hope Into Action, Dr. Fajgenbaum shares best practices for how everyone facing this crisis can get through these scary and trying times together as a community via hope, prayer, action, humor, and the ability to create silver linings. Their discussion also highlights the importance of social distancing for patients with a compromised immune system during COVID-19, the fast-paced nature of research at Dr. Fajgenbaum’s institute, and the advantages of drug repurposing. For more information on drug repurposing Dr. Fajgenbaum and his team are leading, please visit https://cdcn.org/drug-repurposing/.
Feb 24, 2020
Turning Passion Into a Career: Insights from a Physician and Industry Medical Director of AbbVie Pharmaceuticals, Charlotte Owens, MD, FACOG
In this episode, WCG’s President of Patient Advocacy, Steve Smith, talks with Dr. Charlotte Owens, MD, FACOG, Medical Director at AbbVie Pharmaceuticals, who works in the general medicine therapeutic area with a focus on women’s health. As a physician, Dr. Owens describes her passion for pursuing a career that’s truly helpful for others and her desire to educate women on how to bring healthy children into the world. As her career grew into the clinical trials industry, Dr. Owens shares how this passion for helping others grew simultaneously, especially as she saw how bringing new drugs and therapies to market is so impactful in taking care of patients all over the world.
Feb 13, 2020
Biostatistics and Biomarkers for the Reliability and Efficiency of Clinical Trials: A Conversation with Dr. Janet Wittes
In this episode, Dr. Janet Wittes, Founder and President of WCG Statistics Collaborative sits down with WCG’s President of Patient Advocacy, Steve Smith. Their conversation focuses on the importance of reliability and efficiency in clinical trials, and how biostatisticians work closely with clinicians and patients to help ensure clear results from trials. Moreover, they dive into how biomarkers can serve as surrogate endpoints for a trial, especially in the case of rare disease studies.
Feb 13, 2020
An Inside Look at the Role of Data Monitoring Committees with Dr. Jonathan Seltzer
In this episode, WCG’s President of Patient Advocacy, Steve Smith, interviews Dr. Jonathan Seltzer, MD, Chief Scientific Officer at WCG, expert on data safety monitoring boards, biomarkers, biostatistics, and clinical endpoints. During their conversation, Steve and Dr. Seltzer discuss how biomarkers are appropriate for the use of trials, especially when clinical data is tough to get. Part of this discussion turns to Duchenne’s Muscular Dystrophy (an inherited rare muscular disease) on how Patient Advocacy Groups are working with the FDA to define risk vs. benefit, and how promising a biomarker for this condition - as well as many other rare disorders - would be.
Feb 9, 2020
An Interview with Dr. Jeffrey Cooper: Clinical Trial Expert and Participant
In this episode, WCG’s President of Patient Advocacy, Steve Smith, interviews Dr. Jeffrey Cooper, MD, MMM, Vice President of Process & Strategic Improvement at WCG, expert in the conduct of clinical trials, and Parkinson’s patient himself. During their conversation, Steve and Dr. Cooper highlight the strides clinical research has made for many therapeutic areas and the promise research has for individuals across the globe. With a specific focus on Parkinson’s disease, Dr. Cooper dives into his journey as a clinical trial participant and shares his experience on finding a trial, getting enrolled into the study, and his time spent throughout the trial.
Feb 9, 2020
Raising the Patient Voice to Advocate for Change: An Interview with Julia Jenkins of EveryLife Foundation for Rare Disorders
In this episode, Steve Smith, WCG President of Patient Advocacy sits down with Julia Jenkins of the EveryLife Foundation to discuss the impact her organization has on giving patients a voice to legislators on Capitol Hill. Julia shares how patient communities can advocate for public policy changes, improve the FDA-regulatory approval process, and educate on the effectiveness of different trial designs for rare disease drug development. Through their conversation, Steve and Julia underscore the importance of collaboration between all clinical trial stakeholders to improve the study process.
Jan 13, 2020
Ensuring Genetic Counseling is Incorporated Into the Patient Experience: An Interview with Sarah Zentack & Leslie Urdaneta
In this episode, WCG’s President of Patient Advocacy, Steve Smith, sits down with Sarah Zentack, a Certified Genetic Counselor at InformedDNA and Leslie Urdaneta, Family Support Coordinator at the National MPS Society. Their discussion highlights the importance of genetic counseling and the intelligence patients can gain to better understand their treatment options, ensure they’re receiving the correct information and interpretation of results, and feel empowered to make the right choices for their care options.
Jan 13, 2020
Developing Novel Treatments for Rare Disorders: A Look at MPS I with Dr. Emil Kakkis
In this episode, WCG’s President of Patient Advocacy, Steve Smith, talks with Emil Kakkis, MD, PhD, Chief Executive Officer of Ultragenyx Pharmaceuticals and President of the non-profit EveryLife Foundation for Rare Diseases organization. Known for his work in developing an enzyme replacement therapy for the rare disorder MPS I and his connection to the Ryan Foundation, Dr. Kakkis shares with us his experiences in being involved in bringing drugs to market and forming relationships with patients along the way.
Jan 13, 2020
Blazing New Trails in Rare Disease & CNS Clinical Studies: An Interview with Dr. Mark Opler
In this episode, Mark Opler, PhD, MPH, Chief Research Officer at WCG MedAvante-ProPhase sits down with Steve Smith, WCG’s President of Patient Advocacy to discuss the achievements in the field of CNS and rare disease clinical research. Dr. Opler and Steve highlight the unmet need of therapies available for rare disease, the importance of patient enrollment, ensuring efficacy and safety throughout a trial, and how time is of the essence in every study that is conducted.
Jan 13, 2020
An Inside Look at Angelman Syndrome Rare Disease: An Interview with Amanda Moore
In this episode, Amanda Moore, CEO of Angelman Syndrome Foundation speaks with Steve Smith, WCG’s President of Patient Advocacy. As a mom whose son has been diagnosed with Angelman Syndrome - a rare neuro-genetic disorder that affects 1 in 15,000 children - Amanda walks through the time from receiving initial diagnosis to the odyssey of her son’s patient journey in therapy and clinical trials.
Jan 13, 2020
The Role & Importance of Genetic Counselors to Patients: An Interview with Karmen Trzupek of InformedDNA
In this episode, Karmen Trzupek, MS, CGC, Director of Ocular & Rare Disease Genetic Services and Clinical Trial Services at InformedDNA sits down with WCG’s President of Patient Advocacy, Steve Smith. During their conversation, Karmen and Steve talk about the criticality of incorporating genetic counselors into the medical management of a patient’s genetic diagnosis.
Jan 13, 2020
An Inside Look at Ehlers-Danlos Syndrome: An Interview with Sarah Tompkins
In this episode, Sarah Tompkins, Patient Advocate of Ehlers-Danlos Syndrome, chats with WCG’s President of Patient Advocacy, Steve Smith. During their discussion, Sarah shares with us her experience being a patient with a genetic rare disease who is involved in a clinical trial.
Jan 13, 2020
A Father’s Journey and Fight Towards a Cure for MPS I Rare Disease: An Interview with Mark Dant
In this episode, Mark Dant, Founder of the Ryan Foundation speaks with Steve Smith, WCG’s President of Patient Advocacy. Their conversation highlights the importance of Patient Advocacy Groups – and the resources they bring to individuals diagnosed with a disease – as well as the great promise clinical trials bring to patients. Mark shares a personal story of his son, Ryan, who was diagnosed with MPS I, and how Patient Advocacy Groups and clinical trials have positively impacted their lives.
Jan 13, 2020
Learning How to See Differently: An Interview with Kristin Smedley, President of the Curing Retinal Blindness Foundation
In this episode, Kristin Smedley sits down with President of WCG Patient Advocacy, Steve Smith, to talk about the journey her two children with retinal blindness have experienced. Known as the “happiest mom of two blind kids” and a powerful TEDx talker, Kristin highlights the CRB1 rare genetic degenerative disease both of her boys are affected with. She underscores the importance of genetic diagnosis and shares the impact clinical trials and patient advocacy groups have had in finding a cure for this disease.
Nov 18, 2019
Chasing My Cure: an Interview with Dr. Fajgenbaum
In this episode, WCG’s President of Patient Advocacy, Steve Smith, sits down for an interview with Dr. David Fajgenbaum, Assistant Professor of Medicine at the University of Pennsylvania and Author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action. In this podcast, you’ll hear Steve and Dr. Fajgenbaum discuss what it’s like to be a patient of a rare disease – in this case Castleman’s disease – and Dr. Fajgenbaum’s fight to find a cure for his own disease. This is a story of incredible courage and uniquely acquired wisdom. It is a story of triumph over adversity. And it’s a story of life changing, groundbreaking hope.
Aug 13, 2019
The State of Clinical Trials in Autism and Neurodevelopmental Disorders with Dr. Scott Hunter
What’s the state of clinical trials in autism and neurodevelopmental disorders? What’s on the horizon? Scott J. Hunter, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, Chief Research Officer at WCG-MedAvante-ProPhase. Dr. Hunter is a professor of psychiatry and behavioral neuroscience, as well as pediatrics, at the University of Chicago.
Jul 5, 2019
The New Paradigm of Patient Recruitment: an interview with Mark Summers
Despite advances in science and technology, we still see that 80% of clinical trials are running behind on their enrollment timeline. Mark Summers, Founder of WCG ThreeWire, and President of Patient Engagement at WCG, shares his insights on the current industry model of patient recruitment and the philosophy behind the new patient recruitment paradigm. *Things you will learn in this podcast:* * Shortcomings of the current industry model of patient recruitment * How to better plan for and deploy patient recruitment strategies * How to find the most reliable and resource effective patients * The economic philosophy of planning and deploying a patient recruitment program
May 2, 2019
Exciting Developments in Psychopharmacology in 2019 with guest Andrew Cutler, MD
Dr. Andrew J. Cutler shares his insights on the current challenges and opportunities for CNS therapies during an energizing conversation with Dr. Mark Opler, Chief Research Officer at WCG MedAvante-ProPhase. Dr. Cutler is a member of WCG’s Scientific Leadership Team, and a recognized expert in CNS therapies and clinical trials. Dr. Cutler is a sought-after speaker about the evaluation and treatment of mental illnesses such as ADHD, Bipolar Disorder (Manic-Depression), Major Depression, Anxiety Disorders and Schizophrenia. He conducts clinical trials for Phase I-IV studies. Indications include ADHD in children, adolescents and adults, depression, anxiety, bipolar disorder, schizophrenia and other neuropsychiatric and medical conditions. In addition to being the Chief Medical Officer for Meridien Research, Dr. Cutler is a Courtesy Assistant Professor of Psychiatry at the University of Florida.
Apr 27, 2019
The Role of Expert Committees in Clinical Research with guest Jonathan Seltzer, MD, MBA, MA, FACC
Dr. Seltzer, president and founder of ACI Clinical, and chief scientific officer of WCG Clinical, shared his insights on expert committees during a recent conversation with Bill Stedman, manager, member services, ACI Clinical.
Apr 18, 2019
The Most Pressing Challenges and Opportunities in Pain Research with guest Nathaniel Katz, MD, MS
Dr. Katz, Chief Science Officer and the founder of Analgesic Solutions, shared his insights during a recent conversation with Mark Opler, MD, PhD, Chief Research Officer at WCG’s MedAvante-ProPhase. WCG recently acquired Analgesic Solutions.
Mar 27, 2019
Important Trends in CNS Clinical Trials in 2019 with guest Cristoph Correll, MD
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase. Dr. Correll is both a clinical psychiatrist (for both adults and children) and a clinical scientist. His work focuses on the identification, characterization and treatment of adults and youths with severe psychiatric disorders. His particular area of expertise is psychopharmacology.
Mar 6, 2019
The Most Pressing Challenges in Psychiatry Clinical Trials with Leslie Citrome, MD, MPH
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase. Dr. Citrome has a private practice and is clinical professor of psychiatry and behavioral sciences at New York Medical College in Valhalla.